FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.genomics-reporting.r4
Resource TypeDiagnosticReport
IdDiagnosticReport-somaticReport.json
FHIR VersionR4

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: DiagnosticReport somaticReport

Genetic analysis report (Genetics)

When For2023-02-02
Performers Practitioner Test Dolin Organization My Test Pathology Laboratories
Identifier Accession ID/23-0000345

Report Details

CodeValueFlagsNoteWhen ForReported
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Mutations/Megabase [# Ratio] in Tumor29.8Final2023-02-01
Microsatellite instability [Interpretation] in Cancer specimen QualitativeMSI-HFinal2023-02-01
PD-L1 by clone 22C3 in Tissue by Immune stain ReportPositiveFinal5% tumor proportion score2023-02-01
Haplotype NameHLA-A*24:02Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-A*02:06Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-B*35:01Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-B*35:01Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-C*03:03Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-C*15:02Final2023-02-012023-02-01 00:00:00-0500

Patient is positive for Tier 1 / Level A variants, including variants with FDA-approved indications.

Coded Conclusions:

  • Positive

Source1

{
  "resourceType": "DiagnosticReport",
  "id": "somaticReport",
  "meta": {
    "profile": [
      "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomic-report"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomic-study-reference",
      "valueReference": {
        "reference": "Procedure/somaticStudy",
        "display": "somaticStudy"
      }
    }
  ],
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ]
      },
      "value": "23-0000345"
    }
  ],
  "basedOn": [
    {
      "reference": "ServiceRequest/somaticServiceRequest"
    }
  ],
  "status": "final",
  "category": [
    {
      "coding": [
        {
          "system": "http://terminology.hl7.org/CodeSystem/v2-0074",
          "code": "GE",
          "display": "Genetics"
        }
      ]
    }
  ],
  "code": {
    "coding": [
      {
        "system": "http://loinc.org",
        "code": "51969-4",
        "display": "Genetic analysis report"
      }
    ]
  },
  "effectiveDateTime": "2023-02-02",
  "performer": [
    {
      "reference": "Practitioner/pathologistPractitioner"
    },
    {
      "reference": "Organization/performingOrganization"
    }
  ],
  "resultsInterpreter": [
    {
      "reference": "Practitioner/supervisorPractitioner"
    },
    {
      "reference": "Organization/performingOrganization"
    }
  ],
  "result": [
    {
      "reference": "Observation/NOTCH1-uncertain-var"
    },
    {
      "reference": "Observation/ZFHX3-uncertain-var"
    },
    {
      "reference": "Observation/MSH2-del-var"
    },
    {
      "reference": "Observation/NTHL1-snv-var"
    },
    {
      "reference": "Observation/STAG2-insertion-var"
    },
    {
      "reference": "Observation/ATR-insertion-var"
    },
    {
      "reference": "Observation/EGFR-L858R-var"
    },
    {
      "reference": "Observation/ROS1-Fusion-var"
    },
    {
      "reference": "Observation/NOTCH1-significance"
    },
    {
      "reference": "Observation/ZFHX3-significance"
    },
    {
      "reference": "Observation/MSH2-del-disease"
    },
    {
      "reference": "Observation/NTHL1-snv-disease"
    },
    {
      "reference": "Observation/STAG2-insertion-significance"
    },
    {
      "reference": "Observation/ATR-insertion-significance"
    },
    {
      "reference": "Observation/EGFR-L858R-significance"
    },
    {
      "reference": "Observation/ROS1-Fusion-disease"
    },
    {
      "reference": "Observation/ROS1-Fusion-therapuTrial"
    },
    {
      "reference": "Observation/ROS1-Fusion-therapuDrug"
    },
    {
      "reference": "Observation/EGFR-L858R-therapuDrug1"
    },
    {
      "reference": "Observation/EGFR-L858R-therapuDrug2"
    },
    {
      "reference": "Observation/TMB-therapuDrug"
    },
    {
      "reference": "Observation/NOTCH1-uncertain-molc"
    },
    {
      "reference": "Observation/ZFHX3-uncertain-molc"
    },
    {
      "reference": "Observation/MSH2-del-molc"
    },
    {
      "reference": "Observation/NTHL1-snv-molc"
    },
    {
      "reference": "Observation/STAG2-insertion-molc"
    },
    {
      "reference": "Observation/ATR-insertion-molc"
    },
    {
      "reference": "Observation/EGFR-L858R-molc"
    },
    {
      "reference": "Observation/ROS1-Fusion"
    },
    {
      "reference": "Observation/TMBExample"
    },
    {
      "reference": "Observation/MSIExample"
    },
    {
      "reference": "Observation/PDL1Example"
    },
    {
      "reference": "Observation/HLA-A-haplotype1"
    },
    {
      "reference": "Observation/HLA-A-haplotype2"
    },
    {
      "reference": "Observation/HLA-B-haplotype1"
    },
    {
      "reference": "Observation/HLA-B-haplotype2"
    },
    {
      "reference": "Observation/HLA-C-haplotype1"
    },
    {
      "reference": "Observation/HLA-C-haplotype2"
    }
  ],
  "conclusion": "Patient is positive for Tier 1 / Level A variants, including variants with FDA-approved indications.",
  "conclusionCode": [
    {
      "coding": [
        {
          "system": "http://loinc.org",
          "code": "LA6576-8",
          "display": "Positive"
        }
      ]
    }
  ]
}